Introduction
============

Olfaction is known to be impaired by aging. Aging negatively affects the ORN cell system in the olfactory neuroepithelium (OE) ([@B32]). The OE has a unique regenerative stem-cell system, which is maintained by the life-long replenishment of mature ORNs in the luminal layer from the progenitor cells in the basal layer ([@B5]; [@B27]; Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). In steady-status neurogenesis, primitive olfactory progenitor cells differentiate into late progenitor cells and then differentiate into immature ORNs. A variety of stimuli, such as cytokines, neurotrophins, and growth factors, induce differentiation and maturation of immature ORNs ([@B3]; [@B17]; [@B11]).

Neurotrophins and growth factors have important roles in neuronal differentiation, maturation, and maintenance in the steady-state condition ([@B7]), and the dose-dependent differential effects of neurotrophins and growth factors have been reported ([@B30]; [@B26]). Insulin-like growth factor-1 (IGF-1) is a growth factor that promotes neurogenesis and neuronal growth. Although IGF-1 is mainly produced in the liver and skeletal muscles, it is also generated in the central nervous system, where it plays an important role in the differentiation and maturation of neurons ([@B19]; [@B18]; [@B21]). As our previous study showed, reduction in ORN number and cell proliferation in the aged OE reduced gene expression of IGF-1, which may contribute to olfactory impairment during aging ([@B32]). Considering the previous studies, the balance of IGF-1 might be of importance in the regulation of OE homeostasis in the aging population.

We hypothesized that IGF-1 administered at an appropriate dose could restore the aging-induced reduction of ORNs. In the present study, we explored the effects of low-dose and high-dose IGF-1 administration on the ORN cell system in aged mice.

Materials and Methods {#s1}
=====================

Mice
----

Sixteen-month-old male mice (*n* = 6 for each group) were used (C57BL/6, purchased from Saitama Experimental Animals, Saitama, Japan). The mice were maintained in a temperature-controlled (24 ± 1°C) environment under a 12-h light-dark cycle (light on from 09:00 to 21:00). Food and water were available *ad libitum*. All animal experiments were approved by the Animal Care and Use Committee of the University of Tokyo (Approval No. P17-010) and were conducted in accordance with institutional guidelines.

Mouse Model of IGF-1 Administration
-----------------------------------

Mice were injected subcutaneously with 20 μg/kg (low-dose group) and 200 μg/kg (high-dose group) rhIGF-1 (rhIGF-1; Mecasermin, Orphan Pacific, Tokyo, Japan), which is also active in mice ([@B4]; [@B14]), dissolved in sterile saline, three times a week from days 0 to 53 ([@B4]; [@B14]; [@B35]; Figure [1](#F1){ref-type="fig"}). Control mice received saline solution subcutaneously on the same schedule as the rhIGF-1-treated mice. Both control and rhIGF-1-treated mice were sacrificed on day 56.

![Experimental timeline. Mice were injected subcutaneously with 20 μg/kg (low-dose group) and 200 μg/kg (high-dose group) recombinant human insulin-like growth factor-1 (rhIGF-1) or saline three times a week from days 0 to 53. Subsequently, the olfactory epithelium was collected for analysis by immunohistochemistry (IHC).](fnagi-10-00385-g001){#F1}

Tissue Preparation and Histological Analyses
--------------------------------------------

The septal nasal mucosa was harvested and prepared for histological analyses as described previously ([@B31], [@B34],[@B35], [@B32],[@B33]). In brief, all samples were cut at the level of the anterior end of the olfactory bulb. Four-micrometer-thick paraffin sections were deparaffinized and stained with hematoxylin and eosin or immunohistochemically. Antigen-retrieval and blocking of endogenous peroxidase activity were performed before immunostaining. Then, the sections were incubated in Blocking One (Nacalai Tesque, Kyoto, Japan) to block non-specific antibody binding. Primary antibodies against mouse SOX2 (SOX2; 1:300 dilution; rabbit monoclonal, Abcam clone EPR3131; Cambridge, United Kingdom), growth-associated protein 43 (GAP43; 1:1000 dilution; rabbit polyclonal, Novus \#NB300-143B; Littleton, CO, United States), Ki-67 (1:200 dilution; rabbit monoclonal, Novus \#NB600-1252), OMP (OMP; 1:8000 dilution, goat polyclonal, Wako, Osaka, Japan), and cleaved Cas3 (Cas3; 1:300 dilution; rabbit polyclonal, Cell Signaling \#9661; Danvers, MA, United States) were detected with peroxidase-conjugated appropriate secondary antibodies and a diaminobenzidine substrate. In the OE, SOX2 is a transcription factor and expressed by proliferating progenitor cells in the basal layer. GAP43 and OMP are expressed by immature ORNs and mature ORNs, respectively. Ki-67 is a marker for cell proliferation and expressed in all active stages of the cell cycle, and Ki-67-positive cells are particularly detected in the basal layer ([@B32],[@B33]). Caspases are crucial mediators of programmed cell death (apoptosis) and Cas3 is a well-defined activated death protease ([@B23]).

Images of the bilateral septal OE were acquired using a digital microscope (BZ-X700; Keyence, Osaka, Japan) at 400× magnification. Using a previously reported method ([@B32]), the number of OMP^+^ ORNs, GAP43^+^ immature ORNs, and cleaved Cas3^+^ apoptotic cells per 1-mm length areas of the OE and the number of SOX2^+^ ORN progenitors and Ki-67^+^ cells on the basal layer per mm length of the OE were counted manually using digital imaging software (Photoshop CS6; Adobe, San Jose, CA, United States) in a blinded manner.

Statistical Analysis
--------------------

Statistical comparisons among groups were performed by one-way analysis of variance with Tukey *post hoc* tests using the GraphPad Prism software version 6.0 (GraphPad Software Inc., San Diego, CA, United States^[1](#fn01){ref-type="fn"}^). *P* \< 0.05 was considered to be statistically significant.

Results
=======

We first investigated the influence of rhIGF-1 on the cellular composition of the aged OE by comparing the OE of saline-and rhIGF-1-treated mice (low IGF-1, high IGF-1). We found that the number of OMP^+^ mature ORNs was significantly higher in the low-dose rhIGF-1-treated group compared to the saline-treated and high-dose rhIGF-1-treated groups. The number of SOX2^+^ olfactory progenitors also increased only in the low-dose rhIGF-1-treated group. However, the number of GAP43^+^ immature ORNs significantly increased in both the low- and high-dose rhIGF-1-treated groups compared to the saline-treated group (Figures [2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"} and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![Representative images of immunohistological staining (brown) of OMP-positive (OMP^+^) cells **(A)**, SOX2^+^ ORN progenitor cells **(B)**, GAP43^+^ immature ORNs **(C)**, Ki67^+^ proliferating cells **(D)**, and cleaved Cas3^+^ apoptotic cells **(E)**. Each cell except for many OMP^+^ cells is indicated by arrows. Tissue sections were counterstained with the nuclear dye hematoxylin (blue). Numbers of SOX2^+^ ORN progenitors and Ki67^+^ actively proliferating cells per mm of the basal layer and OMP^+^ mature ORNs, GAP43^+^ immature ORNs, and Cas3^+^ apoptotic cells per mm of the OE in saline or rhIGF-1-treated mice. Open circles, rectangles, and triangles represent the values for each mouse in the saline, low-IGF-1, and high-IGF-1 treated groups (each *n* = 6), respectively. The horizontal lines represent the mean value for each group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001; and ^∗∗∗∗^*P* \< 0.0001 (one-way ANOVA).](fnagi-10-00385-g002){#F2}

We next examined the cellular mechanisms underlying the increase of mature and immature ORNs in rhIGF-1-treated mice. As the number of mature ORNs is determined by the balance between proliferation of the ORN precursors and cell death, we analyzed the number of Ki-67^+^ proliferating cells and Cas3^+^ apoptotic cells in the OE. Ki-67^+^ cells were mainly detected in and proximal to the basal layer, where olfactory progenitors and immature ORNs give rise to differentiated progenies. The number of Ki-67^+^ cells was significantly higher in both the low- and high-dose rhIGF-1-treated groups than in the saline-treated group. Interestingly, the number of Cas3^+^ apoptotic cells increased in the rhIGF-1-treated group compared to the saline-treated group, and this increase was more prominent in the high-dose rhIGF-1-treated group. Cas3^+^ cells were mainly detected in the basal and the intermediate layers, where immature ORNs are usually present (Figures [2D](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"} and Supplementary Table [S1](#SM2){ref-type="supplementary-material"}).

Discussion
==========

Here, we demonstrated, for the first time, that low-dose rhIGF-1 administration increased the number of OMP+ mature ORNs in the aged OE, but high-dose rhIGF-1 did not have positive effects on the aged OE. These dose-dependent effects of rhIGF-1 on the aged OE may be important for developing treatments for aging-related olfactory dysfunction.

IGF-1 is a growth factor exerting trophic effects on neuronal development and regeneration in the central nervous system and peripheral nervous system ([@B12]; [@B2]). IGF-1 activates protein synthesis in neurons, glia, oligodendrocytes, and Schwann cells; stimulates the survival of mature and immature neurons, and promotes the proliferation of neuronal precursors ([@B6]; [@B2]), acting neuroprotectively after injury. Thus, IGF-1 controls tissue homeostasis throughout the lifespan via regulation of cell proliferation, survival, and cell death ([@B15]). Recently, IGF-1 was found to have contradictory effects on the regulation of apoptosis. IGF-1 reportedly prevents the expression of apoptosis-associated genes and inhibits apoptotic programs and pathways ([@B22]; [@B13]; [@B8]; [@B36]), but on the other hand, it is considered to induce apoptosis ([@B10]; [@B24]; [@B25]; [@B9]). These different effects may be influenced by the dose, administration route, number of administrations, and the interval between administrations ([@B26]; [@B2]). IGF-1 secretion decreases and the effects of IGF-1 on tissues alter with aging ([@B20]; [@B1]; [@B2]). Therefore, it is reasonable to consider that IGF-1 plays an important role in the prevention and treatment of many neurological diseases such as olfactory and neurodegenerative disorders and hearing loss and IGF-1 therapies at an appropriate dose could provide significant benefits for aged individuals. How IGF-1 acts on OE homeostasis remains unclear. However, considering that IGF-1 and the IGF-1 receptor (IGF-1R) are expressed in the OE and the olfactory bulb ([@B28]; [@B16]) and IGF-1 is transported to the olfactory bulb via the olfactory nerve-related nasal transport ([@B29]), systemic administration of IGF-1 may directly and indirectly influence the OE.

The increase in the number of OMP^+^ mature ORNs after IGF-1 administration can be partly explained by the overwhelmingly higher cell proliferation of olfactory progenitors and immature ORNs compared to the increase in Cas3^+^ apoptotic cells. However, it should be noted that different doses could lead to different effects. We elucidated that high-dose rhIGF-1 administration increased the number of GAP43^+^ immature ORNs and accelerated apoptosis, but on the other hand, it did not cause an increase in the numbers of SOX2^+^ ORN progenitors and OMP^+^ mature ORNs. Collectively, these results indicate that the number of olfactory progenitors and immature and mature ORNs rises only by low-dose rhIGF-1 treatment and that high-dose rhIGF-1 administration did not increase the number of ORN progenitors and only promoted both proliferation and apoptosis of ORN progenitors/ immature ORNs in the aged OE. High-dose IGF-1 may saturate the IGF-1R, and free IGF-1 and the saturated IGF-1 -- IGF-1R complexes could lead to an increase of apoptosis of ORN progenitors/ immature ORNs. Increased apoptosis is likely to be at least partly responsible for the unchanged ORN numbers in the high-dose rhIGF-1-treated mice.

Considering that the reduction in mature ORN numbers is associated with olfactory impairment in the aged population ([@B33]), IGF-1 administered at an appropriate dose could prevent aging-induced negative effects on ORNs. However, because our results were only obtained from mouse studies, care should be taken regarding IGF-1 application for the treatment of human olfactory impairment. Further studies are required to investigate the application of IGF-1 treatment to humans and to determine the appropriate dose of adequate intervals between IGF-1 administrations for the treatment of olfactory deterioration in aged individuals, and to assess the effects of IGF-1 administration on wellness and quality of life.

Low-dose, but not high-dose, rhIGF-1 administration increased the number of OMP+ mature ORNs in the aged OE. IGF-1 administration at an appropriate dose may be a key factor in treatments for aging-related olfactory dysfunction.
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**A,B**: Representative images of the olfactory epithelium (OE) from untreated mice (hematoxylin and eosin stain; **A**, 40× magnification; **B**, 400× magnification). The box in **A** indicates the region of the OE shown in **B**,**C**: Diagram of cell lineage of olfactory receptor neurons (ORN).
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###### 

Change rate of each cell number. Each change rate was calculated by dividing each cell number in the low and high-dose insulin-like growth factor-1 (IGF-1) groups by those in the saline-treated control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; and ^∗∗∗∗^*P* \< 0.0001 (one-way ANOVA). Cas3, caspase-3; GAP43, growth associated protein 43; OMP, olfactory marker protein; ORN, olfactory receptor neuron; SOX2, sex determining region Y-box 2.
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Cas3

:   caspase-3

GAP43

:   growth associated protein 43

IGF-1

:   insulin-like growth factor-1

IGF-1R

:   insulin-like growth factor-1 receptor

OE

:   olfactory epithelium

OMP

:   olfactory marker protein

ORN

:   olfactory receptor neuron

rhIGF-1

:   recombinant human IGF-1

SOX2

:   sex determining region Y-box 2
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